Limitations of the so-called "intensified" insulin therapy in type 1 diabetes mellitus
- PMID: 16389898
- DOI: 10.1016/s1262-3636(05)88267-9
Limitations of the so-called "intensified" insulin therapy in type 1 diabetes mellitus
Abstract
Intensive insulin treatment is defined by basal-prandial insulin therapy which tries to reproduce physiological insulin secretion. This requires 3 to 5 injections and self-monitoring of blood glucose 4 to 5 times a day. Patients who accept their disease and the demanding treatment regimen most often achieve HbA1(c) < 7.5%. Severe complications of diabetes can be avoided without increasing the risk of severe hypoglycemia. However, 50% of type 1 diabetic patients do not reach this objective. The reasons are: the disease itself, the diabetic patient, or the physician. Brittle diabetes with severe, repeated episodes of hypoglycemia and inversely persistent postprandial hyperglycemia prevents patients from reaching the ideal glycemic target. More often, the main obstacle is related to psychological problems: difficulties in self-regulation, denial of the disease, or phobia of hypoglycemia with avoidance behavior. Frequently, young women present eating disorders which can explain the poor diabetes control. The physician himself may be implicated in these poor glycemic results by not prescribing the right tools to obtain optimal glycemic control (staying with just two daily injections with premixed insulin) or by assigning glycemic targets inaccessible for the patient, or when an empathic relationship cannot be established between the patient and the physician. Patient empowerment is the key to the success of functional insulin treatment.
Similar articles
-
Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.Clin Ther. 2004 Apr;26(4):502-10. doi: 10.1016/s0149-2918(04)90052-5. Clin Ther. 2004. PMID: 15189747 Clinical Trial.
-
Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.Diabetes Technol Ther. 2017 Jun;19(6):349-354. doi: 10.1089/dia.2016.0418. Epub 2017 Mar 15. Diabetes Technol Ther. 2017. PMID: 28296467
-
Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately.J Diabetes. 2010 Sep;2(3):194-202. doi: 10.1111/j.1753-0407.2010.00086.x. J Diabetes. 2010. PMID: 20923484
-
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.Postgrad Med. 2016 Jan;128(1):137-44. doi: 10.1080/00325481.2016.1103640. Epub 2015 Nov 7. Postgrad Med. 2016. PMID: 26548422 Review.
-
Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII?Diabetes Metab. 2005 Sep;31(4 Pt 2):4S40-4S44. doi: 10.1016/s1262-3636(05)88266-7. Diabetes Metab. 2005. PMID: 16389897 Review.
Cited by
-
Felix dies natalis, insulin… ceterum autem censeo "beta is better".Acta Diabetol. 2021 Oct;58(10):1287-1306. doi: 10.1007/s00592-021-01737-3. Epub 2021 May 23. Acta Diabetol. 2021. PMID: 34027619 Review.
-
Functional insulin therapy in type 1 diabetics: Short-term effects on weight and nutritional intake.Tunis Med. 2024 Apr 5;102(4):235-240. doi: 10.62438/tunismed.v102i4.4629. Tunis Med. 2024. PMID: 38746964 Free PMC article. French.
-
Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.Am J Transplant. 2010 Sep;10(9):2082-91. doi: 10.1111/j.1600-6143.2010.03212.x. Am J Transplant. 2010. PMID: 20883542 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous